Suppression of ERR targets by a PPARα/Sirt1 complex in the failing heart

Shin-ichi Oka1, Peiyong Zhai, Ralph Alcendor

  • 1University of Medicine and Dentistry of New Jersey, Newark, NJ, USA.

Insights

The PPARα/Sirt1 complex in the heart downregulates estrogen-related receptor (ERR) target genes, contributing to heart failure. This mechanism involves direct interaction with the ERR response element (ERRE) in failing hearts.

Area of Science:

  • Cardiovascular Biology
  • Molecular Cardiology
  • Nuclear Receptor Signaling

Background:

  • Heart failure is a major global health issue.
  • Estrogen-related receptors (ERRs) regulate cardiac genes essential for contraction and mitochondrial function.
  • Dysregulation of ERR target genes is common in heart failure, but the underlying mechanisms are unclear.

Purpose of the Study:

  • To investigate the pathological role of the PPARα/Sirt1 complex in heart failure.
  • To elucidate the molecular mechanism by which PPARα/Sirt1 influences ERR target gene expression in the failing heart.

Main Methods:

  • Utilized mouse models with heterozygous knockout of PPARα or Sirt1, and cardiac-specific bigenic mice.
  • Performed pressure overload to induce left ventricular hypertrophy.
  • Conducted microarray analysis to assess gene expression, particularly of nuclear-encoded mitochondrial genes.
  • Employed reporter gene assays and chromatin immunoprecipitation to study PPARα/Sirt1 interaction with ERREs.

Main Results:

  • Heterozygous knockout of PPARα or Sirt1 attenuated pressure overload-induced cardiac hypertrophy.
  • Cardiac-specific PPARα/Sirt1 bigenic mice exhibited hypertrophy and high mortality.
  • PPARα/Sirt1 bigenic mice showed downregulation of nuclear-encoded mitochondrial genes and mitochondrial abnormalities.
  • PPARα directly bound to and recruited Sirt1 to ERREs, suppressing ERR target gene expression.

Conclusions:

  • The PPARα/Sirt1 complex plays a pathological role in heart failure by downregulating ERR target genes.
  • Direct interaction of PPARα/Sirt1 with ERREs is a key mechanism contributing to cardiac dysfunction in heart failure.
  • Targeting the PPARα/Sirt1 pathway may offer therapeutic strategies for heart failure.

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
The Unfolded Protein Response01:37

The Unfolded Protein Response

The ER is the hub of protein synthesis in a cell. It has robust systems to quality control protein folding and also for degradation of terminally misfolded proteins. Under normal conditions, a small proportion of misfolded proteins that cannot be salvaged need to be transported to the cytoplasm by the ER-associated degradation or ERAD pathways. However, if the ERAD cannot handle the misfolded proteins, the cell activates the unfolded protein response or UPR to adjust the protein folding...
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...